LFVN Lifevantage Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 849146 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-24.8%
TTM net income YoY-73.1%
TTM EPS YoY-73.1%
Revenue 3-yr CAGR-6.9%
Net income 3-yr CAGR2.1%
Margins
Gross margin76.5%
Operating margin2.1%
Net margin1.6%
FCF margin5.1%
EBITDA margin3.8%
Returns
ROE8.2%
ROA4.5%
ROIC (approx.)14.0%
Asset turnover2.85x
Leverage & solvency
Liabilities / assets43.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.81x
Accruals ratio-17.2%
Payout ratio88.2%
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $182.59M | $228.53M |
| Cost of revenue | $40.97M | $44.86M |
| Gross profit | $141.61M | $183.67M |
| R&D expense | $1.00M | $1.40M |
| SG&A expense | $58.42M | $69.21M |
| Operating income | $6.10M | $12.20M |
| Pretax income | $6.07M | $12.24M |
| Income tax | $994,000 | $2.44M |
| Net income | $5.07M | $9.80M |
| EBITDA | $8.87M | $15.36M |
| EPS (basic) | 0.40 | 0.80 |
| EPS (diluted) | 0.40 | 0.75 |
| Dividends declared per share | 0.18 | 0.17 |
| Weighted avg. shares (diluted) | 12.70M | 12.99M |
| Balance sheet | ||
| Cash & equivalents | $14.92M | $20.20M |
| Receivables | $2.99M | $3.29M |
| Inventory | $16.17M | $20.67M |
| Current assets | $38.30M | $50.89M |
| PP&E, net | $7.31M | $6.21M |
| Goodwill | $465,000 | $0 |
| Intangibles | $3.06M | $245,000 |
| Total assets | $62.11M | $71.96M |
| Current liabilities | $20.23M | $27.22M |
| Total liabilities | $28.52M | $37.32M |
| Shareholders' equity | $33.59M | $34.64M |
| Shares outstanding | 12.52M | 12.43M |
| Cash flow statement | ||
| Operating cash flow | $10.24M | $11.88M |
| Capital expenditure | $3.57M | $1.37M |
| Free cash flow | $6.67M | $10.51M |
| Investing cash flow | -$7.31M | -$1.37M |
| Financing cash flow | -$7.78M | -$7.60M |
| Depreciation & amortization | $2.77M | $3.16M |
| Stock-based compensation | $2.35M | $5.70M |
| Dividends paid | $2.34M | $2.07M |
| Share buybacks | $2.04M | $3.15M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.